Experimental pill for advanced cancers with ARID1A mutation
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental pill (TR115) in people whose tumors have a specific gene change (ARID1A mutation). The drug aims to stop cancer growth by blocking a protein involved in cell division, and the study hopes to find out if it works against different types of advanced cancer, including ovarian and endometrial cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your cancer must be advanced and have a specific change (mutation) in a gene called ARID1A.
- You must have had at least one prior treatment (like chemotherapy or immunotherapy) and your cancer must have gotten worse.
- You should be physically active enough to do most daily activities (performance status 0 or 1).
- You must be willing to provide a tumor sample (archived or from a biopsy) for testing.
- You have not been treated before with a drug targeting EZH2 or EZH1/2 that made your cancer worse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
This trial tests a new pill called ASN-3186 for people with advanced solid tumors that haven't responded to standard treatments. The drug may work especially well if your cancer has certain DNA repair problems, like a BRCA mutation.
This trial tests a new medicine (Q901) that targets a specific cell-control pathway to treat advanced cancers that have stopped responding to standard care. It’s mainly for people with certain solid tumor cancers, aiming to see whether the drug can shrink tumors or control disease.
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
This trial tests an experimental pill called DAT-2645 for patients with ovarian cancer that has a BRCA mutation or HRD. It's designed for people who have already tried other treatments, and it works by targeting a specific weakness in the cancer cells.
This trial tests a new pill for advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The pill targets a specific gene change in the cancer, so part of the trial includes genetic testing of your tumor.
Hear when a new Ovarian Clear Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.